Synthes acquisition could boost JNJ

The buy will support efforts to tap growth opportunities in the orthopedics market.

By Trefis Jun 19, 2012 9:26AM
TrefisJohnson & Johnson (JNJ) has received the much-awaited FTC approval to complete the acquisition of Swiss medical device maker Synthes. However, the approval is contingent on Johnson's selling its subsidiary DePuy orthopaedics to Biomet.

The $19.7 billion acquisition could trigger an upside for the company's stock, which recently has been grappling with a host of lawsuits related to its medical devices and diagnostics franchise.

We have a price estimate for JNJ at $74, implying a premium of nearly 15% to the current market price. We will soon be updating our model to reflect the acquisition.


Johnson & Johnson Stock Break-Up

Synthes acquisition to help boost growth

Synthes has a wide portfolio of medical devices for the orthopedics market, including trauma and spine. The combined J&J/Synthes orthopedic division would have the broadest orthopedic portfolio globally.


We believe the acquisition will lend support to the company's efforts to tap growth opportunities in the orthopedics market. J&J expects the trauma and knee markets to grow 7% and believes spine could rebound to a 5% rate of growth.


Further, the acquisition will also bring the Synthes's vast exposure to fast growing emerging countries including China, India and Russia.


More from Trefis

Tags: JNJ
0Comments

DATA PROVIDERS

Copyright © 2014 Microsoft. All rights reserved.

Fundamental company data and historical chart data provided by Morningstar Inc. Real-time index quotes and delayed quotes supplied by Morningstar Inc. Quotes delayed by up to 15 minutes, except where indicated otherwise. Fund summary, fund performance and dividend data provided by Morningstar Inc. Analyst recommendations provided by Zacks Investment Research. StockScouter data provided by Verus Analytics. IPO data provided by Hoover's Inc. Index membership data provided by Morningstar Inc.

STOCK SCOUTER

StockScouter rates stocks from 1 to 10, with 10 being the best, using a system of advanced mathematics to determine a stock's expected risk and return. Ratings are displayed on a bell curve, meaning there will be fewer ratings of 1 and 10 and far more of 4 through 7.

111
111 rated 1
272
272 rated 2
474
474 rated 3
656
656 rated 4
638
638 rated 5
699
699 rated 6
623
623 rated 7
486
486 rated 8
260
260 rated 9
128
128 rated 10
12345678910

Top Picks

SYMBOLNAMERATING
DYNDYNEGY Inc10
TAT&T Inc9
VZVERIZON COMMUNICATIONS9
EXCEXELON CORPORATION8
AAPLAPPLE Inc10
More

VIDEO ON MSN MONEY

ABOUT

Top Stocks provides analysis about the most noteworthy stocks in the market each day, combining some of the best content from around the MSN Money site and the rest of the Web.

Contributors include professional investors and journalists affiliated with MSN Money.

Follow us on Twitter @topstocksmsn.